ERBB2 and neoplasm: A single administration of ErbB2-CAR-CIK cells allowed settlement, infiltration, persistence, and spread at tumor sites, suggesting that ErbB2-CAR-CIK therapy was able to eliminate tumor cells by eliciting long-lasting responses from the innate and adoptive immune systems in addition to the CAR molecule.